Category Archives: Recent News

BriaCell Therapeutics Corp. Announces Completion of Shares for Debt Issuance

BERKELEY, Calif., and VANCOUVER, British Columbia, August 17, 2020 — BriaCell Therapeutics Corp. (“BriaCell” or ...

BriaCell Presents Clinical and Scientific Findings at the Annual Symposium of Society of Surgical Oncology 2020

Preliminary safety and efficacy data are being presented today from the clinical trials of Bria-IMT™ ...

BriaCell Therapeutics Corp. Announces Shares for Debt Issuance

BERKELEY, Calif., and VANCOUVER, British Columbia, August 11, 2020 — BriaCell Therapeutics Corp. (“BriaCell” or ...

BriaCell Files Provisional Patent Application for Novel Treatment and Diagnosis of Coronavirus Disease

BERKELEY, Calif., and VANCOUVER, British Columbia, June 24, 2020 — BriaCell Therapeutics Corp. (“BriaCell” or ...

BriaCell Announces Presentation of Clinical and Scientific Findings at AACR Annual Meeting

Preliminary safety and efficacy data is being presented today from the clinical trials of Bria-IMT™ ...

BriaCell CEO to Present at 3rd Annual Next-Gen Immuno-Oncology Congress in June

BERKELEY, Calif., and VANCOUVER, British Columbia, June 9, 2020 — BriaCell Therapeutics Corp. (“BriaCell” or ...

BriaCell Presents Clinical Findings at 2020 American Society of Clinical Oncology (ASCO) Meeting

Preliminary safety and efficacy data is being presented on May 29 at 9:00 a.m. ET ...

BriaCell Files Patent Application for Novel Immune Therapies for Multiple Disease Indications

BERKELEY, Calif., and VANCOUVER, British Columbia, May 20, 2020 — BriaCell Therapeutics Corp. (“BriaCell” or ...

BriaCell Announces Presentation and Abstract Publication at 2020 American Society of Clinical Oncology (ASCO) Meeting

• New data and pathological findings on BriaCell’s lead candidate, Bria-IMT™, to be Highlighted at ...

BriaCell Continues Business and Clinical Operations During COVID-19 Pandemic

• Phase I/IIa clinical study of BriaCell’s lead candidate, Bria-IMT™, for breast cancer treatment, with ...